menu search

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK, PD, and anti-tumor activity data for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in the second quarter of 2023 Ended first quarter of 2023 with $93.3 million in cash and cash equivalents, with cash runway anticipated into the end of […] The post Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results appeared first on ForexTV... Read More
Posted: May 9 2023, 11:30
Author Name: forextv
Views: 102462

Search within

Pages Search Results: